Impact of Age and Severe Acute Respiratory Syndrome Coronavirus 2 Breakthrough Infection on Humoral Immune Responses After Three Doses of Coronavirus Disease 2019 mRNA Vaccine
Open Forum Infectious Diseases · 03.03.2023 · 10 (3)
DOI: 10.1093/ofid/ofad073 ↗Kurz gefasst
Fachartikel in der Zeitschrift Open Forum Infectious Diseases, online erschienen am 09.02.2023. Verfasst von Francis Mwimanzi und 22 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Health Sciences, Simon Fraser University, Burnaby, Canada. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Public Health Agency of Canada, COVID-19 Immunology Task Force COVID-19 “Hot Spots ”, Canadian Institutes for Health Research.
Abstract (Originalsprache)
Background
Longer-term immune response data after 3 doses of coronavirus disease 2019 (COVID-19) mRNA vaccine remain limited, particularly among older adults and after Omicron breakthrough infection.
Methods
We quantified wild-type- and Omicron-specific serum immunoglobulin (Ig)G levels, angiotensin-converting enzyme 2 displacement activities, and live virus neutralization up to 6 months after third dose in 116 adults aged 24–98 years who remained COVID-19 naive or experienced their first severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection during this time.
Results
Among the 78 participants who remained COVID-19 naive throughout follow up, wild-type- and Omicron-BA.1-specific IgG concentrations were comparable between younger and older adults, although BA.1-specific responses were consistently significantly lower than wild-type-specific responses in both groups. Wild-type- and BA.1-specific IgG concentrations declined at similar rates in COVID-19-naive younger and older adults, with median half-lives ranging from 69 to 78 days. Antiviral antibody functions declined substantially over time in COVID-19-naive individuals, particularly in older adults: by 6 months, BA.1-specific neutralization was undetectable in 96% of older adults, versus 56% of younger adults. Severe acute respiratory syndrome coronavirus 2 infection, experienced by 38 participants, boosted IgG levels and neutralization above those induced by vaccination alone. Nevertheless, BA.1-specific neutralization remained significantly lower than wild-type, with BA.5-specific neutralization lower still. Higher Omicron BA.1-specific neutralization 1 month after third dose was an independent correlate of lower SARS-CoV-2 infection risk.
Conclusions
Results underscore the immune benefits of the third COVID-19 mRNA vaccine dose in adults of all ages and identify vaccine-induced Omicron-specific neutralization as a correlate of protective immunity. Systemic antibody responses and functions however, particularly Omicron-specific neutralization, decline rapidly in COVID-19-naive individuals, particularly in older adults, supporting the need for additional booster doses.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Faculty of Health Sciences, Simon Fraser University, Burnaby, Canada.
- British Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada.
- Division of Medical Microbiology and Virology, St. Paul's Hospital, Vancouver, Canada.
- Department of Medicine, University of British Columbia, Vancouver, Canada.
- Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada.
- British Columbia Centre for Disease Control Public Health Laboratory, Vancouver, Canada.
ORCID-Profile: Chanson J Brumme
Förderung
- Public Health Agency of Canada
- COVID-19 Immunology Task Force COVID-19 “Hot Spots ”
- Canadian Institutes for Health Research
- Coronavirus Variants Rapid Response Network
- Canada Foundation for Innovation through Exceptional Opportunities Fund
- CIHR Canadian HIV Trials Network
- SFU Undergraduate Research
- Michael Smith Foundation for Health Research
Zitieren
APA
Mwimanzi, F., Lapointe, H. R., Cheung, P. K., Sang, Y., Yaseen, F., Kalikawe, R., Datwani, S., Burns, L., Young, L., Leung, V., Ennis, S., Brumme, C. J., Montaner, J. S. G., Dong, W., Prystajecky, N., Lowe, C. F., DeMarco, M. L., Holmes, D. T., Simons, J., …, & Brockman, M. A. (2023). Impact of Age and Severe Acute Respiratory Syndrome Coronavirus 2 Breakthrough Infection on Humoral Immune Responses After Three Doses of Coronavirus Disease 2019 mRNA Vaccine. Open Forum Infectious Diseases, 10(3). https://doi.org/10.1093/ofid/ofad073
Vancouver
Mwimanzi F, Lapointe HR, Cheung PK, Sang Y, Yaseen F, Kalikawe R, et al. Impact of Age and Severe Acute Respiratory Syndrome Coronavirus 2 Breakthrough Infection on Humoral Immune Responses After Three Doses of Coronavirus Disease 2019 mRNA Vaccine. Open Forum Infectious Diseases. 2023;10(3). doi:10.1093/ofid/ofad073
BibTeX
@article{Mwimanzi2023,
author = {Mwimanzi, Francis and Lapointe, Hope R and Cheung, Peter K and Sang, Yurou and Yaseen, Fatima and Kalikawe, Rebecca and Datwani, Sneha and Burns, Laura and Young, Landon and Leung, Victor and Ennis, Siobhan and Brumme, Chanson J and Montaner, Julio S G and Dong, Winnie and Prystajecky, Natalie and Lowe, Christopher F and DeMarco, Mari L and Holmes, Daniel T and Simons, Janet and Niikura, Masahiro and Romney, Marc G and Brumme, Zabrina L and Brockman, Mark A},
title = {Impact of Age and Severe Acute Respiratory Syndrome Coronavirus 2 Breakthrough Infection on Humoral Immune Responses After Three Doses of Coronavirus Disease 2019 mRNA Vaccine},
journal = {Open Forum Infectious Diseases},
year = {2023},
volume = {10},
number = {3},
doi = {10.1093/ofid/ofad073}
}
EUVIMED